Identification of fluid on optical coherence tomography by treating ophthalmologists versus a reading center in the comparison of age-related macular degeneration treatments trials

Retina

Volumn 35, Issue 7, 2015, Pages 1303-1314

  Toth, Cynthia A ^a   Decroos, Francis Char ^a   Ying, Gui Shuang ^b   Stinnett, Sandra S ^a   Heydary, Cynthia S ^a   Burns, Russell ^a   Maguire, Maureen ^b   Martin, Daniel ^c   Jaffe, Glenn J ^a  

^a DUKE UNIVERSITY EYE CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; ARTICLE; CONTROLLED STUDY; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; IMAGE QUALITY; LACRIMAL FLUID; MACULAR THICKNESS; OPHTHALMOLOGIST; OPTICAL COHERENCE TOMOGRAPHY; RETINAL THICKNESS; TREATMENT CONTRAINDICATION; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; BLOOD RETINA BARRIER; CAPILLARY PERMEABILITY; CLINICAL TRIAL; COMPARATIVE STUDY; OPHTHALMOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REPRODUCIBILITY; STANDARDS; SUBRETINAL FLUID; TELECONSULTATION; WET MACULAR DEGENERATION;

ANGIOGENESIS INHIBITORS; BEVACIZUMAB; BLOOD-RETINAL BARRIER; CAPILLARY PERMEABILITY; FLUORESCEIN ANGIOGRAPHY; HUMANS; OPHTHALMOLOGY; RANIBIZUMAB; REMOTE CONSULTATION; REPRODUCIBILITY OF RESULTS; SUBRETINAL FLUID; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84942592863     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000000483     Document Type: Article

References (21)

1. Hee MR, Baumal CR, Puliafito CA, et al. Optical coherence tomography of age-related macular degeneration and choroidal neovascularization. Ophthalmology 1996;103:1260-1270.
2. Ting TD, Oh M, Cox TA, et al. Decreased visual acuity associated with cystoid macular edema in neovascular age-related macular degeneration. Arch Ophthalmol 2002;120:731-737.
3. Rahman W, Chen FK, Yeoh J, da Cruz L. Enhanced depth imaging of the choroid in patients with neovascular agerelated macular degeneration treated with anti-VEGF therapy versus untreated patients. Graefes Arch Clin Exp Ophthalmol 2013;251:1483-1488.
4. Gupta OP, Shienbaum G, Patel AH, et al. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology 2010;117:2134-2140.
5. Dadgostar H, Ventura AA, Chung JY, et al. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration. Ophthalmology 2009;116:1740-1747.
6. Rothenbuehler SP, Waeber D, Brinkmann CK, et al. Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration. Am J Ophthalmol 2009;147:831-837.
7. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-583.
8. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular agerelated macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009;148:43-58 e1.
9. Holz FG, Amoaku W, Donate J, et al. Safety and efficacy of a Flexible dosing regimen of ranibizumab in neovascular agerelated macular degeneration: the SUSTAIN study. Ophthalmology 2011;118:663-671.
10. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
11. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444.
12. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008;246:81-87.
13. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344-1349.
14. Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-1908.
15. CATT. Comparison of age-related macular degeneration treatments trials manual of procedures. Available at: http://www.med.upenn.edu/cpob/studies/documents/CATT ManualofProceduresJan2011.pdf. Accessed April 4, 2013.
16. Ying GS, Huang J, Maguire MG, et al. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology 2013;120:122-129.
17. Rosner B, Glynn RJ, Lee ML. Incorporation of clustering effects for the Wilcoxon rank sum test: a large-sample approach. Biometrics 2003;59:1089-1098.
18. Srinivasan VJ, Wojtkowski M, Witkin AJ, et al. High-definition and 3-dimensional imaging of macular pathologies with high-speed ultrahigh-resolution optical coherence tomography. Ophthalmology 2006;113:2054 e1-14.
19. Wojtkowski M, Bajraszewski T, Gorczynska I, et al. Ophthalmic imaging by spectral optical coherence tomography. Am J Ophthalmol 2004;138:412-419.
20. Sayanagi K, Sharma S, Yamamoto T, et al. Comparison of spectral-domain versus time-domain optical coherence tomography in management of age-related macular degeneration with ranibizumab. Ophthalmology 2009;116:947-955.
21. Folgar FA, Jaffe GJ, Ying GS, et al. Comparison of optical coherence tomography assessments in the comparison of agerelated macular degeneration treatments trials. Ophthalmology 2014;121:1956-1965.